CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00005831
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:23.613401+00:00
Published At: 2013-01-14T00:00:00+00:00
Record Updated At: 2013-01-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Bladder Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Squamous Cell Carcinoma of the Bladder", "Stage IV Bladder Cancer", "Transitional Cell Carcinoma of the Bladder"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2013-01-14"
protocolSection.identificationModule.nctId: "NCT00005831"
protocolSection.identificationModule.officialTitle: "Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.